What patent(s) cover delgocitinib intermediates, and what does “intermediate” mean here?
“Delgocitinib intermediate patent” usually refers to patent filings that claim specific chemical building blocks used to make delgocitinib (or key precursors/advanced intermediates in the manufacturing route), rather than claims on the final drug product itself. These patents can include claims on (1) particular synthesis intermediates, (2) processes for making those intermediates, and (3) sometimes intermediates used in a specific step of the route.
The provided information does not include any patent numbers, assignees, application/publication documents, or jurisdictions for “delgocitinib intermediate patent,” so I can’t identify the exact patents or claim scope.
How long would an intermediate patent last (and why it may not match the drug patent)?
Patent term depends on jurisdiction and filing date, but intermediate (process/chemical) patents often have different expiration timelines than final-composition or formulation patents. Even when they relate to the same product, intermediate patents can expire earlier because they are filed later/earlier in the development chain or because they use different priority dates.
To determine the relevant expiry, you need at least one of the following for the specific “intermediate” patent you mean:
- publication number (e.g., WO/EP/US publication)
- application number
- priority date(s)
- assignee/company
- country (e.g., US vs EP vs JP)
Where to find the right patents for delgocitinib intermediates
A practical way to locate the exact intermediate patents is to search by:
- the drug name: “delgocitinib”
- common synonyms/spelling variants
- the chemical name(s) of key precursors (if you have them)
- assignee/company name(s) linked to delgocitinib development
- CPC/IPC classes for organic synthesis of kinase inhibitors (if you’re searching by structure rather than title)
If you share any one of: a patent publication number, the assignee, or the intermediate’s chemical name, I can help map it to likely related filings (continuations/divisionals, family members, and likely jurisdictions).
Can a generic use expired intermediate patents even if the drug patent is still active?
Sometimes, but it depends on what is claimed:
- If only a specific intermediate is claimed and that intermediate is no longer protected, a manufacturer might still be blocked if the final drug (or a method of use/formulation/process) is still protected.
- If the claims include a manufacturing process step that is required to produce delgocitinib, the generic may still be constrained even if some earlier intermediates are no longer protected.
To answer this for delgocitinib, you’d need the exact claim type(s) (compound vs process vs method-of-use) and the status of the related patents.
What I need from you to answer precisely
Provide one detail and I’ll pin down the correct intermediate patent(s), their jurisdiction, and the likely expiration timeline:
1) a patent/publication number (WO/EP/US/JP), or
2) the assignee/company name, or
3) the chemical name or structure description of the intermediate, or
4) the country you care about (US, EP, China, etc.).
Sources
No patent sources were provided in your message, so I cited none.